Publication: Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases.
| dc.contributor.author | Anders, Carey K | |
| dc.contributor.author | Van Swearingen, Amanda E D | |
| dc.contributor.author | Neman, Josh | |
| dc.contributor.author | Joyce, Johanna A | |
| dc.contributor.author | Cittelly, Diana M | |
| dc.contributor.author | Valiente, Manuel | |
| dc.contributor.author | Zimmer, Alexandra S | |
| dc.contributor.author | Floyd, Scott R | |
| dc.contributor.author | Dhakal, Ajay | |
| dc.contributor.author | Sengupta, Soma | |
| dc.contributor.author | Ahluwalia, Manmeet S | |
| dc.contributor.author | Nagpal, Seema | |
| dc.contributor.author | Kumthekar, Priya U | |
| dc.contributor.author | Emerson, Sam | |
| dc.contributor.author | Basho, Reva | |
| dc.contributor.author | Beal, Kathryn | |
| dc.contributor.author | Moss, Nelson S | |
| dc.contributor.author | Razis, Evangelia D | |
| dc.contributor.author | Yang, Jonathan T | |
| dc.contributor.author | Sammons, Sarah L | |
| dc.contributor.author | Sahebjam, Solmaz | |
| dc.contributor.author | Tawbi, Hussein A | |
| dc.contributor.funder | Asociación Española Contra el Cáncer | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Fundación La Caixa | |
| dc.contributor.funder | National Cancer Center (Estados Unidos) | |
| dc.date.accessioned | 2026-11-18T10:22:45Z | |
| dc.date.available | 2026-11-18T10:22:45Z | |
| dc.date.issued | 2025-03-04 | |
| dc.description | C.K.A. is a Translating Duke Health Scholar. S.R.F. receives salary support from National Institutes of Health (NIH) grants (5U01-TR003715-02, 5R44-CA228694-05/4R44-CA228694-05, 5R01-NS100866-05, and R21-AG077075-01). J.A.J. receives funding from the Swiss National Science Foundation Advanced Grant (TMAG-3_209224), Ludwig Institute for Cancer Research, Breast Cancer Research Foundation, and The Mark Foundation. D.M.C. receives funding from NIH (R37CA227984) and the US Department of Defense (DOD) (W81XWH-22-1-0042). M.V. receives funding through the European Research Council (ERC) (ID: 864759), Fundación AECC (PRYCO234528VALI), and Fundación La Caixa (HR23-00051). Investigators at Memorial Sloan Kettering are supported in part by NIH/National Cancer Institute (NCI) P30 CA008748. Conflict of interest statement. C.K.A. reports research funding (grants or contracts) from PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, AstraZeneca, Elucida, Incyclix, Beigene; receipt of consulting fees from Genentech, Eisai, IPSEN, Seattle Genetics; Astra Zeneca, Novartis, Immunomedics, Elucida, Athenex, and Roche; and receipt of royalties from UpToDate and Jones and Bartlett outside the submitted work. J.A.J. has received research support for her laboratory from the Ludwig Institute for Cancer Research, the University of Lausanne, the Swiss National Science Foundation Advanced Grant (TMAG-3_209224), Breast Cancer Research Foundation, Carigest Foundation, and Fondation SIREC; consulting fees from t-Kinfe Therapeutics and Pionyr Therapeutics; honoraria for speaking at symposia organized by Bristol Meyer Squibb; and an unpaid role on the European Association for Cancer Research Board. D.M.C. has received research funding from the NIH (1R01CA290813-01, R37 CA227984-01) and DoD (BCRP BC210460); and honoraria from the University of Southern California, West Virginia University, and San Antonio Breast Cancer Symposium (SABCS); as well as support for attending a meeting from SABCS. M.V. reports receiving research funds from an AstraZeneca research grant; honoraria from MEDSIR; and a leadership/fiduciary role on the EANO Board and Metastasis Research Society Board. S.R.F. reports support from the American Cancer Society (grant MBGI-1252459) and the NIH (R21CA286097, U01TR003715). A.D. reports funding for a trial paid to the institution from Celcuity and Puma; service on the advisory board of Eli Lilly, Gilead Science, and AstraZeneca; honoraria from OncLive/MJH Life Sciences, WebMD, and Empire State Hematology/Oncology Society. S. Sengupta reports consulting fees from Mayfield Scholar Award (to institution) and Imvax; meeting attendance support from the Society of Neuro-Oncology, provisional patents (no royalties), and participation on a Data Safety Monitoring Committee/Advisory Board for Bexion. M.S.A. receives research funding (to institution) from NIH (1R01CA277728-01A1, 1R01CA264017-01A1), consulting fees from Bayer, Xoft, Apollomics, Viewray, Cairn Threrapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem Therapeutics, GT Medical Technologies, Allovir, EquilliumBio, QV Bioelectronics, Servier Pharmaceuticals, Incyte, and Recordati; participates on a Data Safety Monitoring Board/Advisory Board for VBI Vaccines, Modifibioscience, and Bugworks; has stock/stock options in Mimivax, Cytodyn, MedimmovateAdvisors LLC, and Trisalus Lifesciences. S.N. reports consulting fees from Daiichi Sankyo, Novartis, Telix, Enclear, and Plus Therapeutics. P.U.K. reports receipt of grants/contracts from Genentech and Novocure; consulting fees from Belay Diagnostics, FYR Diagnostics, Plus Therapeutics, Enclear Therapeutics, Affinia Therapeutics, Biocept, Janssen, Bioclinica, Mirati, Novocure, Servier, Telix Pharmaceuticals, and Biodexa; honoraria from Seagen; a provisional patent (WO2016/205367) with no financial incentive or gain; and participation on a Data Safety Monitoring/Advisory Board for BPGBio and In8bio. R.B. reports receipt of grants/contracts (to institution) from Metavivor Foundation, Genentech, and AstraZeneca; consulting fees from AstraZeneca, Seattle Genetics, Genentech, Gilead, Pfizer, Novartis, and Eli Lilly; honoraria from MJH Healthcare, Medscape, Curio Science, MD Outlook, and Aptitude Health; meeting/travel support from MJH Healthcare; leadership/fiduciary role on a board/committee with NCI (ComboMATCH National PI), Roche (INAVO 122 and 123 Steering Committees), and AstraZeneca (DB-RESPOND Steering Committee), and employment with the Ellison Medical Institute. N.S.M. receives research funding (to institution) from AstraZeneca, GT Medical Technologies, and Amgen; consulting fees from AstraZeneca; and honoraria from Varian. E.D.R. reports receiving support for meeting attendance/travel from Gilead, Servier, Integris, AstraZeneca, BMS, Roch, Genesis Pharma, and Pfizer; and participation on a Data Safety Monitoring/Advisory Board with honoraria from AstraZeneca, Servier, and Novartis. S. Sammons reports consulting fees from Foundation Medicine, AstraZeneca, Daiichi Sankyo, Eli Lilly, Pfizer, Incyclix, Relay, Gilead, Sermonix, and Novartis; and research funding (to institution) from AstraZeneca, Eli Lilly, Relay, Seagen, Sermonix, and Novartis. S. Sahebjam reports receipt of honoraria from the National Cancer Institute and PDQ Editorial Board; has served on advisory board committees (with consulting compensation) for Pliant Therapeutics and Telix Pharmaceuticals; and has served in a leadership or fiduciary role for the Society for Neuro-Oncology (Co-Chair, Public Policy Committee). H.A.T. has received research funding from Bristol Myers-Squibb, Novartis, Merck, Genentech, Eisai, Dragonfly Therapeutics, GlaxoSmithKline, Regeneron, and Syntrix; and consulting fees from Bristol Myers-Squibb, Genentech, Merck, Novartis, Regeneron, Medicenna, Iovance, Eisai, Pfizer, Io Biotech, Krystal Biotech, T-Knife Therapeutics, Corcept Therapeutics, and Strand Therapeutics. The other authors (A.E.D.V., J.N., A.S.Z., S.E., K.B., J.T.Y.) have nothing to disclose. | |
| dc.description.abstract | Brain metastases (BrM) arising from solid tumors is an ever-increasing and often devastating clinical challenge impacting hundreds of thousands of patients annually worldwide. As systemic anticancer therapies, and thus survival, improve, the risk for central nervous system (CNS) recurrence has increased. Historically, patients with BrM were excluded from clinical trials; however, there has been a shift toward increasing inclusion over the past decade. To most effectively design the next generation of clinical trials for patients with BrM, a multidisciplinary team spanning local and systemic therapies is imperative. CIMARa (Consortium for Intracranial Metastasis Academic Research), formalized in June 2021, is an inclusive group of multidisciplinary clinical investigators, research scientists, and advocates who share the collective goal of improving outcomes for patients with BrM. CIMARa aims to improve outcomes through the development, coordination, and awareness of multi-institutional clinical trials testing novel therapeutic agents for this unique patient population alongside the translation of preclinical research to the clinical setting. | |
| dc.description.peerreviewed | Sí | |
| dc.format.number | 1 | |
| dc.format.page | vdaf049 | |
| dc.format.volume | 7 | |
| dc.identifier.citation | Neurooncol Adv . 2025 Mar 4;7(1):vdaf049 | |
| dc.identifier.doi | 10.1093/noajnl/vdaf049 | |
| dc.identifier.e-issn | 2632-2498 | |
| dc.identifier.journal | Neuro-oncology advances | |
| dc.identifier.pubmedID | 40276376 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/27840 | |
| dc.language.iso | eng | |
| dc.publisher | Oxford | |
| dc.relation.publisherversion | https://doi.org/10.1093/noajnl/vdaf049 | |
| dc.repisalud.institucion | CNIO | |
| dc.repisalud.orgCNIO | Grupo de Metastasis Cerebral | |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | brain metastases | |
| dc.subject | central nervous system metastases | |
| dc.subject | clinical trials | |
| dc.subject | consortium | |
| dc.subject | research | |
| dc.title | Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 9ff41ae3-2484-4d1c-bfb4-9f7a64487317 | |
| relation.isAuthorOfPublication.latestForDiscovery | 9ff41ae3-2484-4d1c-bfb4-9f7a64487317 | |
| relation.isFunderOfPublication | 453a1189-9bca-4be8-8d60-695f50fe028b | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | f04d23ec-a91d-4242-88b0-cc436888f8a2 | |
| relation.isFunderOfPublication | 6eb6e0c4-0136-4dfc-9723-45a38ca1d7c0 | |
| relation.isFunderOfPublication.latestForDiscovery | 453a1189-9bca-4be8-8d60-695f50fe028b |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- consortiumforintracranial_2026.pdf
- Size:
- 14.92 MB
- Format:
- Adobe Portable Document Format


